Accueil   Diary - News   All news Consortium including ElsaLys Biotech and Novadiscovery awarded €3.35 million by Bpifrance to advance inolimomab in graft-versus-host disease

Consortium including ElsaLys Biotech and Novadiscovery awarded €3.35 million by Bpifrance to advance inolimomab in graft-versus-host disease

 

 

 

  • NOVA awarded €2.4 million to leverage Jinkō®, its best-in-class clinical trial simulation platform, to conduct in silico studies for graft-versus-host disease

 

  • Research academic teams of the consortium - Institut de Recherche Saint Louis1 & Institut Mondor de Recherche Biomédicale 2 - to receive €0.95 million for their collaborative work with ElsaLys on in vitro and in vivo mechanisms of action of inolimomab

 

  • ElsaLys Biotech utilising in silico studies to accelerate the European approval of inolimomab in both adult and paediatric populations with this rare and lifethreatening disease

 

 

Lyon, France – 19 January 2021: The Silikotac Program consortium, consisting of ElsaLys Biotech, Novadiscovery (“NOVA”) and two expert academic teams from Hôpital St Louis (Paris) and Hôpital Henri Mondor (Paris), has been awarded €3.35 million in non-dilutive funding by Bpifrance to support development of inolimomab in graft-versus-host disease (GvHD), the main complication that may occur after an allogeneic hematopoietic stem cell transplantation. The ambition of the Silikotac Program is to create the first French industrial and scientific immunotherapy chain group focused on GvHD.

 


This financing is part of the PSPC (Projet de recherche et développement Structurant pour la Compétitivité) program fund from Bpifrance, a financing initiative from the French government to support new and emerging industries within France.

 

 

Read the press release